Dr. Reddy’s Laboratories to Engage with Investors in June 2025

Dr Reddy’s Laboratories ( (RDY) ) has provided an update.

On May 28, 2025, Dr. Reddy’s Laboratories announced its participation in upcoming investor conferences scheduled for June 5, 2025. The company will engage in both virtual and in-person meetings with institutional investors, organized by the New York Stock Exchange and Investec. These meetings are part of the company’s ongoing efforts to maintain transparency and engage with stakeholders, potentially impacting investor relations and market perceptions.

The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.

Spark’s Take on RDY Stock

According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.

Dr Reddy’s Laboratories receives a solid overall score due to its strong financial performance, especially in revenue growth and balance sheet stability. Technical indicators show positive momentum, although the stock is below its long-term average. Valuation is reasonable, but dividend yield is low. The recent earnings call was positive, highlighting growth and strategic advancements despite some market challenges.

To see Spark’s full report on RDY stock, click here.

More about Dr Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited is a pharmaceutical company based in Hyderabad, India. It is engaged in the development, manufacture, and marketing of a wide range of pharmaceutical products, with a focus on generic medicines, active pharmaceutical ingredients, and proprietary products. The company operates globally, with a significant presence in the United States and other international markets.

Average Trading Volume: 2,076,095

Technical Sentiment Signal: Buy

Current Market Cap: $12.14B

See more data about RDY stock on TipRanks’ Stock Analysis page.